Recently, the Securities Times reported that "the CSRC statistics show that as of October 27, the Shenzhen Huada Gene IPO audit status is shown as a suspension of review. The suspension shows that the application process is not complete, etc., resulting in the review process cannot continue." The big gene is the domestic gene sequencing leader. The company submitted the public prospectus (declaration draft) in December last year. The doctor has also reported it. See "Hua Da Gene is finally going to be listed, and the China Securities Regulatory Commission has issued a pre-disclosure prospectus."

On November 3, Huada Gene Company issued an announcement in response to the matter. The announcement is as follows:

Recently, some media reported that the company was suspended due to the suspension of IPO documents. After the company has been informed of the above contents, it has been verified as follows:

The original personnel of the company's IPO intermediaries can no longer serve as the company for the company due to personal reasons such as career development. According to the relevant regulations, the replacement of the intermediary agency personnel needs to perform the suspension review process, so the company IPO suspension review, not The IPO files are not uniform.

The Huada Gene IPO document was discontinued and reviewed: responded to the replacement of the handling staff

Recently, the handling staff has been replaced, the company has received a notice of recovery review, and it is expected that the updated audit status will be announced in the near future.

The company's IPO is progressing steadily. According to the progress, the company will strictly implement the corresponding decision-making and approval procedures in accordance with the relevant laws and regulations and relevant regulations of the CSRC, and fulfill the information disclosure obligations in a timely manner. All company information is subject to the company announcement.

Special announcement.

Shenzhen Huada Gene Co., Ltd.

November 3, 2016

Vitamin & Nurtures Medicine

PRODUCT SPECIFICATION NORMAL PACKING
Calcium Gluconate Inj. 10% 10ml 50amps/Box
FeSO4 + Folic Acid Tab.(200mg+1mg) 1000`S/Tin
Neurozin (Vitamin Complex) Syrup 240ml 1's/Bottle
Vitamin A+D Soft Capsule 10,000+3,000iu 500`S/Tin
Vitamin B1 Injection 100mg/Ml 10'sx10tray/Box
Vitamin B Complex Injection (B12+B1+B6) 2ml
(B1+B2+B6) 10ml
10`s/Box
50Vials/Box
Vitamin B6 Inj. 100mg/Ml 10'sx10tray/Box
Vitamin B12 Inj. 1mg/2ml 0.5mg/Ml 100amps/Box
Vitamin C Inj. 500mg/5ml
Mutifavoured Tablet 1g
100amps/Box
10's/Tin
Vitamin D3 Inj. 600mg/Ml 10`s/Box
Vitamin K1 Inj. 10mg/Ml 10`s/Box
Vitamin K3 Inj. 10mg/Ml 10`s/Box

Vitamin A&D Capsules,Vitamin K 10Mg Injection,Multivitamin Calcium Syrup,Calcium Gluconate Injection Uses

NINGBO VOICE BIOCHEMIC CO. LTD , https://www.medicine-voice.com